Article
High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution.
Cancer cytopathology - 1 Aug 2020
Jug Rachel, Foo Wen-Chi, Jones Claudia, Ahmadi Sara, Jiang Xiaoyin Sara
Abstract excerpt
BACKGROUND: The ThyroSeq panel tests for genetic alterations to risk-stratify cytologically indeterminate nodules. The authors assessed the test performance of the tests, including the latest version (v3), at an academic center. METHODS: Results from ThyroSeq testing (v2 and v3) were reviewed over 2 years, and patient demographics, cytology diagnoses, results of ThyroSeq testing, and histopathologic diagnoses on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.